stars 1 stars 2 stars 3

ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Our goal is to change treatment paradigms in orphan and rare disease—specifically targeting the chronic inflammatory pathway while avoiding immuno-suppression. TAVNEOS, our first commercial drug product, and each of our drug candidates are designed to selectively block a specific chemoattractant receptor. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.

View Top Employees from ChemoCentryx
Ticker CCXI
Revenue $36 million
Funding $576.1 million
Employees 150 (150 on RocketReach)
Founded 1997
Address 835 Industrial Road Suite 600, San Carlos, California 94070, US
Phone (650) 210-2900
Fax (650) 210-2910
JavaScript, HTML, PHP +49 more (view full list)
Category Biotechnology Research, Pharmaceuticals, Biotechnology, Biopharmaceutical, Healthcare, Science and Engineering, Oral Therapies, Health Care, Autoimmune Diseases, Medical Device, Inflammatory Disorders, Orphan And Rare Diseases, Pancreatic Cancer, Diabetic Nephropathy, ANCA-associated vasculitis, Atypical Hemolytic Uremic Syndrome, Chemokine And Chemoattractant Receptors
Web Rank 8 Million
Keywords chemocentryx, chemocentryx pipeline, avacopan, avacopan compassionate use, chemocentryx,inc
Competitors Abivax, Alios BioPharma, Catabasis Pharmaceuticals, Inc., Onconova Therapeutics, Sage Therapeutics
SIC 283, 28
NAICS 325, 32541, 32, 3254

ChemoCentryx Questions

The ChemoCentryx annual revenue was $36 million in 2023.

Penglie Zhang is the Vice President, Head of Chemistry of ChemoCentryx.

150 people are employed at ChemoCentryx.

ChemoCentryx is based in San Carlos, California.

The NAICS codes for ChemoCentryx are [325, 32541, 32, 3254].

The SIC codes for ChemoCentryx are [283, 28].

Top ChemoCentryx Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
G2Crowd Trusted
300K+ Plugin Users